DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Yes, emerging research. Wegovy reduces hsCRP ~30% independent of weight loss. May explain cardiovascular benefit and emerging applications in MASH, kidney disease, and Alzheimer's research.
Wegovy shows substantial anti-inflammatory effects beyond weight-loss-driven mechanisms. SELECT cardiovascular trial showed hsCRP (high-sensitivity C-reactive protein, key inflammation marker) dropped ~30% within 12 weeks — before significant weight loss had occurred. This appears to explain cardiovascular benefit (MACE reduction) partially independent of weight. Emerging applications: MASH (metabolic-associated steatohepatitis) showed improvement in Phase 3 trial. Kidney disease — FLOW trial showed renal protection in T2D with CKD. Alzheimer's — large Phase 3 trial ongoing 2025-2027 (EVOKE).
Editorial answer verified against FDA labeling and peer-reviewed trials, with sources cited. Not medical advice. Coordinate treatment decisions with your prescriber.